We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Assessment of serum fractalkine level as potential role for complications in splenectomized and non-splenectomized patients with ß-thalassemia major.
- Authors
Awad, Ayat Saeed; Ali, Hanaa Addai; Althalmi, Safaa Abdazahra Alwan
- Abstract
Introduction: Thalassemia is a serious genetic blood related condition characterized by a lack of or malfunctioning hemoglobin in the RBCs. One of the most widespread inherited disorders is beta thalassemia (ß-TM). The high susceptibility to infection in these individuals' is related to high mortality and morbidity rates. Fractalkine is known as CX3C chemokine ligand 1 (CX3CL1), which contains a total of 371 amino acid, and participates in a number of functions, including repair of tissues after injury, immunological response during inflammation, and chemotaxis effet. Methodology: A case control study, containing sixty patients recognized as suffering from ß-TM, was conducted at Al Zahra Teaching Hospital, Najaf (Iraq). The patients were divided into two groups; splenectomized and non-splenectomized patients. The thalassemia disease was enrolled in the "Thalassemia Unit". Suitable statistical techniques were used to analyze the outcomes. Results: In the current study, a significant increase in serum level of CX3CL1 was found in patients with ß-TM, especially in splenectomized group (14.914 ± 2.636), (P = 0.01) and non-splenectomy (13.816 ± 2.686), (P = 0.05) group as compared with control group (12.26 ± 1.797). The linear regression analysis showed that a significant positive correlation in ferritin with serum CX3CL1 level in splenectomy patients with ß-TM group. ROC curve for CX3CL1 that might be diagnosis of patients with ß-TM with an AUC of 0.757 (95% CI: 0.623-0.890), sensitivity and specificity equally 75% and 83.3%. Conclusion: Increase level of CX3CL1 due to its interaction with CX3CR1 receptor may lead to buildup of inflammatory cells in the ß-TM patients, blocking CX3CL1 signaling may be helpful for patients with ß-TM.
- Subjects
NAJAF (Iraq); SPLENECTOMY; FRACTALKINE; BETA-Thalassemia; RECEIVER operating characteristic curves; CHEMOKINE receptors; TEACHING hospitals
- Publication
Anaesthesia, Pain & Intensive Care, 2023, Vol 27, Issue 5, p495
- ISSN
1607-8322
- Publication type
Article
- DOI
10.35975/apic.v27i5.2302